Compare APWC & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APWC | IMA |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | Taiwan | United States |
| Employees | N/A | 15 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.1M | 54.8M |
| IPO Year | 1997 | N/A |
| Metric | APWC | IMA |
|---|---|---|
| Price | $1.38 | $5.85 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 5.6K | ★ 400.8K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $3.94 |
| 52 Week High | $2.34 | $17.50 |
| Indicator | APWC | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 50.19 |
| Support Level | $1.27 | $3.94 |
| Resistance Level | $1.47 | $7.04 |
| Average True Range (ATR) | 0.07 | 0.46 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 63.45 | 54.17 |
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, PRC, Hong Kong and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.